Autoimmune Indication definition

Autoimmune Indication means the treatment or prophylaxis of any autoimmune disease or condition (i.e., any disease or condition that is caused by dis- or de-regulation of the immune system leading to tissue injury by a reaction to an endogenous antigen but that is not primarily a malignant neoplasia).
Sample 1Sample 2Sample 3
Autoimmune Indication means the treatment or prophylaxis of any autoimmune disease or condition (i.e. any disease or condition that is caused by dis-or de-regulation of the immune system leading to tissue injury by a reaction to an endogenous antigen but that is not primarily a malignant neoplasia).
Sample 1Sample 2Sample 3
Autoimmune Indication means an Indication for autoimmune disease mediated by immune system cells, including cells with B cell lineage.
Sample 1

Examples of Autoimmune Indication in a sentence

  • ZKC shall have one opportunity to exercise its right of first negotiation in connection with such Other Autoimmune Indication by providing Corixa an executed letter of intent to enter into good faith negotiations for a license regarding the Licensed Product related to such Other Autoimmune Indication within thirty (30) days of receipt of such notice from Corixa.

  • Thereafter, Corixa and ZKC shall have thirty (30) days from Corixa's receipt of such letter of intent to negotiate and enter into an agreement covering a license for such Other Autoimmune Indication.

  • The terms of any such license shall be negotiated in good faith for each parties' mutual benefit, and shall reflect the fair market value with respect to such Other Autoimmune Indication, taking into account factors such as market size, margins, cost of manufacture and price comparables.

  • If the Second Royalty-Bearing Product reaches the Start of Phase III prior to the time that the First Royalty Bearing Product reaches the Start of Phase III, then the event payment would be *** dollars ($***) because the Second Royalty-Bearing Product is the first Autoimmune Indication to reach the Start of Phase III.

  • If after the First Royalty-Bearing Product reaches the Start of Phase IIb, any Royalty-Bearing Product in an Autoimmune Indication different than the Autoimmune Indication of the First Royalty-Bearing Product reaches the Start of Phase IIa (the “Second Royalty-Bearing Product”), then the event payment would be *** dollars ($***).

  • Taylor McKague: Needs guidance on what and when to book things for this year’s fair, will stay in contact with Neal Keefe to get advice and direction.

  • For each country in the ROW Territory for which PDL has exercised its option to be the exclusive marketing and selling party of Daclizumab for a specified Autoimmune Indication, upon such exercise, (a) the provisions of Section 2B.4(b) shall apply and (b) PDL shall automatically be granted a nonexclusive license under all Roche Patents, Roche Know-How, PDL Patents and PDL Know-How to the extent required or useful for the purposes of carrying out such PDL marketing and selling activities.

  • The applicable royalty rates on Net Autoimmune Sales shall depend for each country in the ROW Territory and for each Autoimmune Indication on whether X.

  • With respect to each Autoimmune Indication, within thirty (30) days after the date of the first filing by X.

  • Xxxxx shall use commercially reasonable efforts to diligently market and sell Daclizumab for that Autoimmune Indication in that country in the ROW Territory.

Related to Autoimmune Indication

  • Biomarker means a parameter or characteristic in a patient or Patient Sample, the measurement of which is useful (a) for purposes of selecting appropriate therapies or patient populations or monitoring disease susceptibility, severity or state, or monitoring therapies for such patient and/or (b) for predicting the outcome of a particular treatment of such patient.

  • Biological product means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human beings.

  • Phase III Clinical Trial means a human clinical trial of a product, the design of which is acknowledged by the FDA to be sufficient for such clinical trial to satisfy the requirements of 21 C.F.R. 312.21(c) (as amended or any replacement thereof), or a similar human clinical trial prescribed by the Regulatory Authority in a country other than the United States, the design of which is acknowledged by such Regulatory Authority to be sufficient for such clinical trial to satisfy the requirements of a pivotal efficacy and safety clinical trial.

  • Marijuana product means marijuana as defined in 50-32-101 and marijuana-infused products